PMAP-36 reduces the innate immune response induced by Bordetella bronchiseptica-derived outer membrane vesicles

Balhuizen, Melanie D.; Versluis, Chantal M.; Harten, Roel M. van; Jonge, Eline F. de; Brouwers, Jos F.; Lest, Chris H.A. van de; Veldhuizen, Edwin J.A.; Tommassen, Jan; Haagsman, Henk P.

doi:10.1016/j.crmicr.2020.100010

Cited by 14 publications

(36 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yet another method to increase OMV release is the induction of membrane stress by supplementation of external molecules, as was shown for naturally occurring antimicrobial peptides (AMPs; Manning and Kuehn, 2011 ; Balhuizen et al, 2021 ). These OMVs have been named peptide induced OMVs (pOMVs).…”

Section: Induction and Isolation Of Omvs For Therapeutic Purposesmentioning

confidence: 99%

“…As discussed above, increased OMV production may be a means of the bacterium to protect from induced stress. Bordetella bronchiseptica pOMVs resulting from induction by the porcine myeloid antimicrobial peptide 36 (PMAP-36) were indeed shown to contain PMAP-36 ( Balhuizen et al, 2021 ). Furthermore, pOMVs contained relatively more phosphatidylglycerol compared to sOMVs, a negatively charged lipid, which might interact with the positively charged AMP.…”

Section: Induction and Isolation Of Omvs For Therapeutic Purposesmentioning

confidence: 99%

“…Furthermore, pOMVs contained relatively more phosphatidylglycerol compared to sOMVs, a negatively charged lipid, which might interact with the positively charged AMP. Bordetella bronchiseptica pOMVs were also shown to have decreased thermal stability compared to sOMVs, possibly due to the presence of PMAP-36 in the membrane ( Balhuizen et al, 2021 ). As for peptide-based antibiotics, such as polymyxin B, also these molecules were shown to induce OMV release ( Kulkarni et al, 2015 ).…”

Section: Induction and Isolation Of Omvs For Therapeutic Purposesmentioning

confidence: 99%

“…Additionally, hOMVs had a large increase in the amount of lysophospholipids, as was shown by lipidomic analysis. Despite these differences, hOMVs evoked a comparable immune response to spontaneous OMVs in vitro ( Balhuizen et al, 2021 ). However, the quantities of LPS might still pose a problem and molecules to modulate the resulting immune response are needed.…”

Section: Future Prospectsmentioning

confidence: 99%

“…Several methods exist to induce OMV release in bacterial cultures and increase OMV yields ( Klimentová and Stulík, 2015 ). However, these induced OMVs may have different properties compared to OMVs that are spontaneously released from bacteria ( Collins, 2011 ; Schwechheimer and Kuehn, 2013 ; Michel et al, 2020 ; Balhuizen et al, 2021 ). In this review, we describe the different methods used to induce OMVs and to compare the properties of the resulting vesicles.…”

Section: Introduction On Outer Membrane Vesiclesmentioning

confidence: 99%

See 4 more Smart Citations

Outer Membrane Vesicle Induction and Isolation for Vaccine Development

2021

Self Cite

View full text Add to dashboard Cite

Gram-negative bacteria release vesicular structures from their outer membrane, so called outer membrane vesicles (OMVs). OMVs have a variety of functions such as waste disposal, communication, and antigen or toxin delivery. These vesicles are the promising structures for vaccine development since OMVs carry many surface antigens that are identical to the bacterial surface. However, isolation is often difficult and results in low yields. Several methods to enhance OMV yield exist, but these do affect the resulting OMVs. In this review, our current knowledge about OMVs will be presented. Different methods to induce OMVs will be reviewed and their advantages and disadvantages will be discussed. The effects of the induction and isolation methods used in several immunological studies on OMVs will be compared. Finally, the challenges for OMV-based vaccine development will be examined and one example of a successful OMV-based vaccine will be presented.

show abstract

Section: Induction and Isolation Of Omvs For Therapeutic Purposesmentioning

confidence: 99%

Section: Induction and Isolation Of Omvs For Therapeutic Purposesmentioning

confidence: 99%

Section: Induction and Isolation Of Omvs For Therapeutic Purposesmentioning

confidence: 99%

Section: Future Prospectsmentioning

confidence: 99%

Section: Introduction On Outer Membrane Vesiclesmentioning

confidence: 99%

See 3 more Smart Citations

Outer Membrane Vesicle Induction and Isolation for Vaccine Development

2021

Self Cite

View full text Add to dashboard Cite

show abstract

Outer membrane vesicles as biomimetic vaccine carriers against infections and cancers

Rani

Alzubaidi

Butt

et al. 2022

WIREs Nanomed Nanobiotechnol

View full text Add to dashboard Cite

In the last decade, nanoparticle‐based therapeutic modalities have emerged as promising treatment options for cancer and infectious diseases. To improve prognosis, chemotherapeutic and antimicrobial drugs must be delivered selectively to the target sites. Researchers have increasingly focused their efforts on improving drug delivery, with a particular emphasis on cancer and infectious diseases. When drugs are administered systemically, they become diluted and can diffuse to all tissues but only until the immune system intervenes and quickly removes them from circulation. To enhance and prolong the systemic circulation of drugs, nanocarriers have been explored and used; however, nanocarriers have a major drawback in that they can trigger immune responses. Numerous nanocarriers for optimal drug delivery have been developed using innovative and effective biointerface technologies. Autologous cell‐derived drug carriers, such as outer membrane vesicles (OMVs), have demonstrated improved bioavailability and reduced toxicity. Thus, this study investigates the use of biomimetic OMVs as biomimetic vaccine carriers against infections and cancers to improve our understanding in the field of nanotechnology. In addition, discussion on the advantages, disadvantages, and future prospects of OMVs will also be explored. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease Biology‐Inspired Nanomaterials > Protein and Virus‐Based Structures

show abstract

Bacterial extracellular vesicles: biotechnological perspective for enhanced productivity

Muñoz-Echeverri,

Benavides-López,

Geiger

et al. 2024

World J Microbiol Biotechnol

View full text Add to dashboard Cite

Bacterial extracellular vesicles (BEVs) are non-replicative nanostructures released by Gram-negative and Gram-positive bacteria as a survival mechanism and inter- and intraspecific communication mechanism. Due to BEVs physical, biochemical, and biofunctional characteristics, there is interest in producing and using them in developing new therapeutics, vaccines, or delivery systems. However, BEV release is typically low, limiting their application. Here, we provide a biotechnological perspective to enhance BEV production, highlighting current strategies. The strategies include the production of hypervesiculating strains through gene modification, bacteria culture under stress conditions, and artificial vesicles production. We discussed the effect of these production strategies on BEVs types, morphology, composition, and activity. Furthermore, we summarized general aspects of BEV biogenesis, functional capabilities, and applications, framing their current importance and the need to produce them in abundance. This review will expand the knowledge about the range of strategies associated with BEV bioprocesses to increase their productivity and extend their application possibilities. Graphical abstract

show abstract

PMAP-36 reduces the innate immune response induced by Bordetella bronchiseptica-derived outer membrane vesicles

Cited by 14 publications

References 52 publications

Outer Membrane Vesicle Induction and Isolation for Vaccine Development

Outer Membrane Vesicle Induction and Isolation for Vaccine Development

Outer membrane vesicles as biomimetic vaccine carriers against infections and cancers

Bacterial extracellular vesicles: biotechnological perspective for enhanced productivity

Contact Info

Product

Resources

About